|Articles|June 13, 2022
Pharmacy Clinical Pearl: Geographic Tongue
Author(s)Saro Arakelians, PharmD
Geographic tongue is an inflammatory but harmless condition affecting the surface of the tongue.
Advertisement
Insight
- The tongue is normally covered with pinkish-white, tiny bumps (papillae), which are fine, hairlike, short projections.
- With geographic tongue, patches on the surface of the tongue are missing papillae and appear as red, smooth “islands,” often with slightly raised borders.
- These patches, or lesions, give the tongue a geographic, or map-like, appearance.
- The lesions often heal in 1 area and then migrate to a different part of the tongue.
- Geographic tongue is also known as benign migratory glossitis.
- Symptoms include discomfort and pain; irregular, red, and smooth patches; and frequent changes in the location, shape, and size.
- Risk factors may include family history and fissured tongue.
- Treatment includes mouth rinses with anesthetics, antihistamines, and corticosteroids; OTC pain relievers; and vitamin B supplements.
Articles in this issue
over 3 years ago
Article
Half of Parents Regularly Give Their Children Dietary Supplements, Poll ShowsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
2
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5